Figure 4.
Syngeneic prophylactic vaccination against T cell lymphoma
(A) Schematic representation of the timeline used for prophylactic vaccination using the OVA protein.
(B and C) Assessment of tumor growth volume (B) and survival (C) of animals challenged with the EG.7 tumor following prophylactic vaccination using nOVA-/aOVA-pulsed mature DCs.
(D) Quantification of TCM and Teff CD4 and CD8 T cells derived from mice immunized with nOVA-/aOVA-pulsed mature DCs from vaccinated animals shown in (B and C).
(E) Luminex analysis of cytokine/chemokine production in response to in vitro re-stimulation of T cell isolated from vaccinated animals shown in (B and C). Cytokines/chemokines with the highest fold change are depicted in red. For (B–D), n = 10/group with ∗∗∗p < 0.001. For (E), n = 5/group. See also Figure S5. All studies presented in (B–D) were repeated two times.